Integer Holdings Co. (NASDAQ:ITGR) shares traded up 6.1% on Monday . The company traded as high as $23.60 and last traded at $23.56, with a volume of 662,339 shares changing hands. The stock had previously closed at $22.21.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Integer Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday. Sterne Agee CRT restated a “buy” rating on shares of Integer Holdings in a research report on Monday, May 16th. Finally, TheStreet downgraded Integer Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Integer Holdings has a consensus rating of “Hold” and an average target price of $57.00.

The company’s market capitalization is $690.10 million. The stock has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00.

Integer Holdings (NASDAQ:ITGR) last announced its earnings results on Thursday, July 28th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by $0.14. The firm earned $348.38 million during the quarter, compared to analyst estimates of $356.72 million. Integer Holdings’s revenue for the quarter was up 99.2% on a year-over-year basis. During the same period last year, the firm posted $0.73 earnings per share. Analysts anticipate that Integer Holdings Co. will post $3.23 EPS for the current year.

Greatbatch, Inc is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.